BHRT + GLP-1 for Perimenopause: Should You Stack Them?

Perimenopausal women on Winona, Hers, or Inner Balance are increasingly asking whether to add a GLP-1 — or vice versa. The honest answer from the evidence is that hormone therapy and GLP-1 receptor agonists do different things. Hormone therapy does not produce weight loss; the Cochrane review of 28 RCTs (Norman 2000^[1]) found a mean body-weight difference of about 0.03 kg vs placebo. A GLP-1 produces 14–21% body-weight reduction at full dose (Wilding 2021^[9], Jastreboff 2022^[8]) and the SURMOUNT post-hoc by reproductive stage (Tchang 2025^[2]) showed the effect is preserved through perimenopause. The two therapies are complementary, not substitutes — with one important pharmacokinetic wrinkle on the oral-hormone side.

The honest summary

• HRT and BHRT do not produce weight loss. Cochrane Norman 2000^[1] pooled 28 RCTs of oestrogen +/- progestogen vs placebo (n ~ 28,559) and found essentially no body-weight effect. The NAMS 2022 position statement^[3] reaches the same conclusion: HRT is not a weight-loss intervention.
• GLP-1 efficacy is preserved through perimenopause. Tchang 2025 (SURMOUNT post-hoc by reproductive stage^[2]) reported 26% body-weight reduction in premenopausal women, 23% in perimenopausal women, and 23% in postmenopausal women on tirzepatide 15 mg — all vs 2–3% on placebo. The menopausal metabolic shift does not blunt the drug effect.
• Stacking is safe — with route mattering. Transdermal estradiol patches, vaginal estradiol, and the progesterone IUD bypass the GLP-1 gastric-emptying interaction entirely. Oral HRT and oral combined contraceptives can have meaningful Cmax and AUC reductions on tirzepatide during titration (Min 2025^[7]).
• Compounded BHRT is not categorically different from FDA-approved HRT when the molecule (17-beta-estradiol, micronized progesterone) is the same and the compounding pharmacy is PCAB-accredited. The “personalized hormone testing” marketing layer has weak evidence behind it.

What HRT actually does (and does not) for weight

The single most-cited evidence base on hormone therapy and body weight is the Cochrane review by Norman 2000^[1]. The review pooled 28 randomized controlled trials of oestrogen-only or oestrogen-plus-progestogen vs placebo and reported a weighted mean difference in body weight that did not reach clinical or statistical significance — effectively zero. The NAMS 2022 position statement^[3] reviewed the more recent evidence and reached the same headline: HRT does not cause weight gain, does not cause weight loss, and should not be prescribed for either reason.

What HRT does do, per NAMS 2022^[3] and the Younglove 2026 clinical review^[6], is shift body composition modestly. Several observational analyses and secondary endpoints suggest estradiol attenuates the perimenopausal accumulation of visceral adipose tissue and preserves lean mass — both of which are mechanistically consistent with the perimenopausal metabolic shift Lovejoy 2008^[4] documented (rising VAT and falling resting energy expenditure independent of total body weight). The composition signal is real; the scale signal is not.

What the SURMOUNT post-hoc actually showed

Tchang 2025 (Obesity^[2]) is the cleanest evidence on GLP-1 efficacy in women by reproductive stage. The analysis pooled women from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4, categorized them by FSH and menstrual history into premenopausal, perimenopausal, and postmenopausal strata, and reported total body-weight change on tirzepatide 15 mg at 72 weeks:

• Premenopausal women: −26% body weight on tirzepatide 15 mg vs −3% placebo.
• Perimenopausal women: −23% on tirzepatide 15 mg vs −2% placebo.
• Postmenopausal women: −23% on tirzepatide 15 mg vs −3% placebo.
• Responder rate: 97–98% of women in every reproductive-stage subgroup achieved at least 5% weight loss on tirzepatide.

The clinical interpretation is straightforward: the menopausal transition does not blunt the magnitude of the GLP-1 effect. A perimenopausal woman starting Zepbound or Wegovy should expect the same response curve as a younger premenopausal patient, not a discounted version of it.

Compounded BHRT vs FDA-approved HRT — what is actually different

Compounded bio-identical hormone therapy (BHRT) and FDA-approved HRT differ less than the marketing suggests when the molecule is the same. 17-beta-estradiol delivered via a Winona compounded transdermal cream and 17-beta-estradiol delivered via an FDA-approved patch (Climara, Vivelle-Dot) are the same molecule. Micronized progesterone in a compounded capsule and Prometrium are the same molecule. The difference is regulatory: FDA-approved products have batch-level GMP oversight and prescriber-label consistency; PCAB-accredited compounding pharmacies have lab-verified concentration but no FDA bioavailability data.

Where the marketing tends to outrun the evidence is the “personalized hormone testing” layer that many BHRT clinics use to justify customized formulations. The NAMS 2022 position statement^[3] explicitly notes that salivary hormone monitoring and the resulting custom dose titration lack supporting evidence; serum or transdermal delivery dosing per standard ranges is what the trial data support. Practically, a patient on Winona or Hers transdermal estradiol is receiving the same therapeutic molecule as a patient on a hospital-prescribed Climara patch — with the caveat that the compounded product does not have an FDA-approved Cmax/AUC profile and should not be assumed bioequivalent dose-for-dose.

Magnitude: HRT alone vs GLP-1 alone vs stacked, at 12 months

The drug-interaction question: route of HRT delivery matters

The Min 2025 PK/DDI review^[7] aggregated the Eli Lilly tirzepatide oral-contraceptive PK study and related GLP-1 data. The headline numbers for an oral combined ethinyl estradiol + norgestimate contraceptive co-administered with tirzepatide 5 mg single dose were roughly Cmax −55% to −66% and AUC −20% to −23% for ethinyl estradiol, with similar directional effects on the progestin. The mechanism is delayed gastric emptying reducing peak oral absorption. The clinical implication is for oral hormonal contraception, not standard postmenopausal oral HRT — but the same PK signal predicts measurable Cmax reductions for oral estradiol valerate (Estrace) and oral micronized progesterone during tirzepatide and Foundayo titration.

Routes that bypass the interaction entirely:

• Transdermal estradiol patch (FDA-approved Climara, Vivelle-Dot, or compounded equivalent from Winona or Hers) — first-pass absorption is dermal, gastric emptying is irrelevant.
• Vaginal estradiol (Vagifem tablets, Estring ring, compounded cream) — local mucosal absorption, no PK interaction with any GLP-1.
• Progesterone IUD (Mirena, Liletta) for the progestin half of combined therapy — local uterine effect.
• Topical micronized progesterone cream for symptomatic dosing — though serum levels are modest and uterine protection requires either oral progesterone or IUD when systemic estradiol is also being delivered.

For semaglutide and the once-daily oral semaglutide (Rybelsus), the PK effect on oral contraceptives is smaller but non-zero. Liraglutide and dulaglutide have minimal documented effect on oral hormone PK in the Min 2025 review^[7].

NAMS 2022 risk-benefit framework for HRT in women on a GLP-1

The NAMS 2022 position statement^[3] remains the canonical risk-benefit framework. The benefit-risk ratio favors HRT for symptomatic women under 60 or within 10 years of their final menstrual period, with the lowest effective dose and the shortest duration consistent with treatment goals. The risks that drove the WHI signal (Rossouw 2002 JAMA^[5]) — venous thromboembolism, stroke, and a small breast-cancer signal in the estrogen-plus-progestin arm — were concentrated in women starting HRT a decade or more after menopause and in oral combined therapy. Transdermal estradiol carries a lower VTE signal than oral.

Adding a GLP-1 does not change the NAMS framework. A 45-year-old perimenopausal woman with symptomatic vasomotor symptoms and a BMI of 34 is a candidate for both HRT and a GLP-1 on independent indications; the GLP-1 is not a substitute for symptom control, and HRT is not a substitute for weight reduction. The Younglove 2026 review^[6] reaches the same conclusion: combination therapy is reasonable when each component has a separate indication, and the synergy on visceral adiposity and lean mass preservation is mechanistically plausible but not yet confirmed by RCT.

The provider ecosystem: Winona, Hers, Inner Balance, and Joi

Winona prescribes compounded transdermal estradiol cream and oral micronized progesterone via PCAB-accredited compounding pharmacies. The transdermal route is GLP-1-compatible; the oral progesterone has a minor PK consideration during tirzepatide titration but does not require dose adjustment in NAMS 2022 guidance.

Hers prescribes FDA-approved transdermal estradiol patches and oral progesterone alongside their GLP-1 program. Same PK profile as a hospital-prescribed regimen.

Inner Balance and Joi Women's Wellness sit closer to the compounded-BHRT end of the spectrum, with personalized formulations and salivary or serum monitoring. The molecules dispensed are the same; the monitoring layer is what NAMS 2022^[3] notes lacks evidence.

Practical protocol for stacking

1. Treat the indication, not the side effect. HRT for vasomotor symptoms, sleep, and bone protection per NAMS 2022^[3]. GLP-1 for BMI ≥ 30 or BMI ≥ 27 with comorbidity. Do not prescribe HRT for weight loss; the Cochrane data^[1] are unambiguous.
2. Default to transdermal estradiol. Patches (Climara, Vivelle-Dot, Winona cream) bypass the GLP-1 PK interaction and carry a lower VTE risk than oral per the WHI follow-up data.
3. For oral combined contraception during perimenopause, use barrier backup during tirzepatide and Foundayo titration weeks. Re-counsel at each dose increase per Min 2025^[7].
4. Anticipate breakthrough bleeding on oral progesterone during a GLP-1 dose-escalation week and do not assume it represents a problem with the HRT regimen.
5. Maintain the lean-mass protocol. 1.6–2.0 g/kg protein and 2–3 resistance sessions per week matter more in perimenopause, when baseline lean-mass loss is already accelerated per Lovejoy 2008^[4].
6. Baseline DEXA for bone density at HRT and GLP-1 initiation in women over 50; repeat at 12–24 months. WHI long-term data^[5] show HRT preserves hip and spine BMD; combined GLP-1-only weight loss can accelerate bone loss.

Related research and tools

• GLP-1s for perimenopause weight loss — the Tchang 2025 SURMOUNT post-hoc in detail
• HRT, perimenopause, and GLP-1 weight management — the NAMS 2022 framework applied to combination therapy
• GLP-1 + HRT + estrogen during menopause — estrogen biology and the metabolic transition
• HRT and weight loss evidence — the Cochrane Norman 2000 review in depth
• GLP-1, menstrual cycle, and hormone interactions — cycle changes and ovulation on a GLP-1
• GLP-1, fertility, PCOS, and pregnancy — reproductive-stage transitions adjacent to perimenopause

Important disclaimer. This article is educational and does not constitute medical advice. Hormone therapy decisions depend on personal and family history of breast cancer, venous thromboembolism, cardiovascular disease, and the timing relative to the final menstrual period — the NAMS 2022 framework should be applied by a qualified clinician. Compounded BHRT products do not have FDA-approved bioequivalence data; dosing should be coordinated with the prescribing clinician. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if new RCT data on HRT plus GLP-1 combination therapy or on BHRT bioequivalence is published.